Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 transdermal cannabidiol in pediatric autism spectrum disorder
ACTRN12619000216112Phase 2Completed
- Sponsor
- Zynerba Pharmaceuticals
- Start
- May 2019
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Zygel in Autism Spectrum Disorder (ASD), sponsored by Zynerba Pharmaceuticals. Primary endpoint: Safety and tolerability of ZYN002. Started May 2019; status: completed.
02
Drugs
Zygel
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ACTRN12619000216112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000216112.